Should You Avoid AutoZone Stock, Even Near a 52-Week Low?
Source: The Motley Fool
AutoZone shares are down 26.9% over the past year and sit near 52-week lows (~4.3% above), despite reporting 8.4% third-quarter fiscal 2026 sales growth (ended May 9). The stock’s valuation reset narrative is supported by MegaHub expansion (156 hubs today, including 14 opened in Q3, aiming for ~300) and stronger commercial momentum (commercial sales up 10.4%, 29% of total sales). Offsetting concerns include softer do-it-yourself foot traffic from tight consumer budgets, weather-driven air-conditioning parts weakness, and guidance for lower year-over-year top-line growth due to tougher comps from prior inflation/tariff price spikes; the board also added $1.5B to buybacks in June (~3% of market cap).
Analysis
The selloff looks more like the market de-rating a late-cycle compounder than a call on the core business. If MegaHub improves fill-rate and route density, the incremental winner is not just AZO’s commercial mix but its working capital profile: higher turnover and better service levels can compound faster than headline same-store sales suggest. The second-order loser is the fragmented independents and small regional distributors that cannot match hub-and-spoke inventory depth, even if that pressure is not yet visible in the reported numbers.
Near term, the stock likely trades on traffic data and guidance cadence rather than strategy execution. The key risk is that commercial share gains are real but not fast enough to offset DIY softness, weather distortion, and tougher comparisons, which would keep the multiple pinned for 1-2 quarters. A buyback can cushion downside, but it does not solve the main question: whether earnings growth re-accelerates enough to justify a rerating versus peers.
Contrarian read: the market may be overstating the permanence of the slowdown and underappreciating that a cheaper multiple plus aggressive repurchases can lift EPS even with mediocre top-line growth. That said, the consensus long case depends on sustained commercial momentum; if that slips to mid-single digits or if management lowers the 6-12 month hub rollout/traffic outlook, the value thesis breaks. Relative value is better than outright beta here, because the stock’s downside is more about narrative reset than balance-sheet stress.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment
Key Decisions for Investors
- Initiate a small long AZO / short ORLY pair over 3-6 months: thesis is valuation gap overstates AZO risk if commercial share gains persist; stop if AZO commercial growth falls below high-single digits or ORLY re-accelerates relative comps.
- Add AZO only on a retest of the prior lows, using a 6-12 month horizon: downside is limited by buybacks, while upside is a 10-15% multiple rerating if the next print confirms commercial momentum; cut if management turns more cautious on traffic or guide.
- Avoid chasing ORLY long here as a defensive proxy; the risk/reward is less attractive after its relative outperformance, and it is more exposed if the market rotates back toward valuation discipline.
- Watch for a commercial-growth inflection in the next earnings cycle: if growth stays near double digits, expect the market to move from 'valuation reset' to 'earnings durability,' which could unlock multiple expansion.
More News
- OpenAI projected to bring in $20bn less in revenue than expected
- Nvidia, Oracle, CoreWeave and other AI stocks sink on OpenAI revenue report
- Nvidia-backed Aussie AI firm Firmus withdraws historic IPO, citing market volatility
- Trump presents national medal to Microsoft CEO after suspending its H-1B visas and alleging ‘foreign indentured servants’ replaced domestic workers
- TSMC taps GlobalFoundries to bolster US silicon interposer production in $2B deal
- Premarket movers: Palantir gains on bullish call, NXP tumbles on downgrade
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework